Bio/Pharma News

Takeda Faces Cancer Lawsuits with $2.4 Billion in Settlements

April 30, 2015

Takeda Pharmaceutical agrees to pay $2.4 billion to settle lawsuits from patients and family members who said the diabetes drug Actos caused bladder cancer.

Mylan Rejects Teva’s $40 Billion Offer

April 29, 2015

In a seething letter, Mylan’s executive chairman announced the unanimous rejection of a $40-billion unsolicited acquisition offer from Teva.

Mylan Ups Offer to Perrigo to More than $32 Billion

April 29, 2015

After rejecting Teva’s unsolicited $40 billion purchase offer, Mylan has increased its own offer to purchase Perrigo from $29 billion to over $32 billion in cash in stocks.

Mylan Recalls Injectables Due to Visible Particulate Matter

April 28, 2015

PTSM: Pharmaceutical Technology Sourcing and Management

Mylan announces a recall of eight lots of injectable products due to visible foreign particulate matter.

Innate Pharma Announces $1.3 Billion Collaboration with AstraZeneca

April 27, 2015

Innate Pharma announces a co-development and commercialization agreement with AstraZeneca to accelerate the development of Innate’s anti-NKG2A antibody.

EMA Recommends Authorization of Melanoma Treatment

April 24, 2015

The agency has recommended granting marketing authorization for Opdivo.

Hospira Recalls Bupivacaine HCl Injection

April 24, 2015

The company voluntarily recalls Preservative-Free Bupivacaine HCl Injection, USP due to potential iron oxide particulates.

Pfizer Receives Breakthrough Therapy Designation for Xalkori

April 21, 2015

FDA grants Pfizer Breakthrough Therapy designation for its treatment of ROS1-positive non-small cell lung cancer.

Endolysin Technology Presents an Antibiotic Alternative with Broad Applicability

April 21, 2015

Endolysin technology targets unwanted bacteria, including resistant strains

Teva Proposes $40 Billion to Acquire Mylan

April 21, 2015

Teva announces that it would pay up to $40 billion in cash and stock to acquire Mylan.